Kinetic modeling of 3′-deoxy-3′-fluorothymidine in somatic tumors: Mathematical studies

Journal of Nuclear Medicine

Volumn 46, Issue 2, 2005, Pages 371-380

  Muzi, Mark ^a,b   Mankoff, David A ^a   Grierson, John R ^a   Wells, Joanne M ^a   Vesselle, Hubert ^a   Krohn, Kenneth A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

3 deoxy 3 fluorothymidine; Compartmental modeling; Kinetic analysis; Thymidine kinase 1

Indexed keywords

3' DEOXY 3' FLUOROTHYMIDINE F 18; 3' FLUOROTHYMIDINE; UNCLASSIFIED DRUG; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CELL KINETICS; CELL PROLIFERATION; DRUG RETENTION; DRUG UPTAKE; LUNG CANCER; MATHEMATICAL ANALYSIS; MOLECULAR MODEL; PLASMA CLEARANCE; PRIORITY JOURNAL; SIMULATION; TUMOR; ALGORITHM; BIOLOGICAL MODEL; CANCER STAGING; COMPUTER ASSISTED DIAGNOSIS; COMPUTER SIMULATION; EVALUATION; ISOTOPE DILUTION ASSAY; KINETICS; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; NEOPLASM; PATHOLOGY; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION;

ALGORITHMS; CELL PROLIFERATION; COMPUTER SIMULATION; DIDEOXYNUCLEOSIDES; IMAGE INTERPRETATION, COMPUTER-ASSISTED; KINETICS; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; NEOPLASM STAGING; NEOPLASMS; RADIOISOTOPE DILUTION TECHNIQUE; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION;

EID: 15844426940     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Shields AF, Grierson JR, Kozawa SM, Zheng M. Development of labeled thymidine analogs for imaging tumor proliferation. Nucl Med Biol. 1996;23:17-22.
2. 11C]thymidine in patients with squamous cell carcinoma of the head and neck. Acta Oncol 1996;35:737-741.
3. Shields AF, Mankoff DA, Link JM, et al. Carbon-11-thymidine and FDG to measure therapy response. J Nucl Med. 1998;39:1757-1762.
4. 11C] thymidine positron emission tomography in tumoral and non-tumoral cerebral lesions. Acta Neurol Belg. 1999;99:118-125.
5. Eary JF, Mankoff DA, Spence AM, et al. 2-[C-11]thymidine imaging of malignant brain tumors. Cancer Res. 1999;59:615-621.
6. 11C]thymidine PET imaging studies of malignant brain tumors: preliminary patient results. Mol Imaging. 2002;1:145-150.
7. Cleaver JE. The relationship between the rate of DNA synthesis and its inhibition by ultraviolet light in mammalian cells. Radiat Res. 1967;30:795-810.
8. 18F]FLT utilisation in colorectal cancer. Eur J Nucl Med Mol Imaging. 2004;31:169-178.
9. Shields AF, Grierson JR, Muzik O, et al. Kinetics of 3′-deoxy- 3′-[F-18]fluorothymidine uptake and retention in dogs. Mol Imaging Biol. 2002;4:83-89.
10. Muzi MJ, Vesselle H, Grierson JR, et al. Kinetic analysis of 3′-deoxy-3′-fluorothymidine PET studies: validation studies in patients with lung cancer. J Nucl Med. 2005;46:274-282.
11. Kong XB, Zhu QY, Vidal PM, et al. Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3′-fluoro-3′-deoxythymidine and 3′-azido-3′-deoxythymidine. Antimicrob Agents Chemother. 1992;36:808-818.
12. Sherley JL, Kelly TJ. Regulation of human thymidine kinase during the cell cycle. J Biol Chem. 1988;263:8350-8358.
13. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med. 2002;43:1210-1217.
14. Schwartz JL, Tamura Y, Jordan R, Grierson JR, Krohn KA. Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs. J Nucl Med. 2003;44:2027-2032.
15. 18F]FLT) in pancreatic cancer cell lines. Eur J Nucl Med Mol Imaging. 2002;29:1174-1181.
16. m 5′-nucleotidase and 5′(3′)-deoxyribonucleotidase in substrate cycles involved in nucleotide metabolism. J Biol Chem. 2001;276:6185-6190.
17. Grierson JR, Schwartz JL, Muzi M, Jordan R, Krohn KA. Metabolism of 3′-deoxy-3′-[F-18]fluorothymidine (FLT) in proliferating A549 cells: validations for positron emission tomography (PET). Nucl Med Biol 2004;31:829-837.
18. Mankoff DA, Shields AF, Graham MM, et al. Kinetic analysis of 2-[C-11]thymidine PET imaging studies: compartmental model and mathematical analysis. J Nucl Med. 1998;39:1043-1055.
19. 11C]thymidine PET imaging studies: validation studies. J Nucl Med. 1999;40:614-624.
20. 18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-cell lymphoma model and in the human disease. Cancer Res. 2003;63:2681-2687.
21. Eriksson S, Kierdaszuk B, Munch-Petersen B, Oberg B, Johansson NG. Comparison of the substrate specificities of human thymidine kinase 1 and 2 and deoxycytidine kinase toward antiviral and cytostatic nucleoside analogs. Biochem Biophys Res Commun. 1991;176:586-592.
22. Munch-Petersen B, Cloos L, Tyrsted G, Eriksson S. Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides. J Biol Chem. 1991;266:9032-9038.
23. Lundgren B, Bottiger D, Ljungdahl-Stahle E, et al. Antiviral effects of 3′-fluorothymidine and 3′-azidothymidine in cynomolgus monkeys infected with simian immunodeficiency virus. J Acquir Immune Defic Syndr. 1991;4:489-498.
24. Belt JA, Marina NM, Phelps DA, Crawford CR. Nucleoside transport in normal and neoplastic cells. Adv Enzyme Regul. 1993;33:235-252.
25. Mackey JR, Mani RS, Seiner M, et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res. 1998;58:4349-4357.
26. Gray JH, Mangravite LM, Owen RP, et al. Functional and genetic diversity in the concentrative nucleoside transporter, CNT1, in human populations. Mol Pharmacol. 2004;65:512-519.
27. Goldman D, Bowen D, Gewirtz DA. Some considerations in the experimental approach to distinguishing between membrane transport and intracellular disposition of antineoplastic agents, with specific reference to fluorodeoxyuridine, actinomycin D, and methotrexate. Cancer Treat Rep. 1981;65(suppl):43-56.
28. 3H]thymidine uptake in rodent and canine neoplasms-concise communication. J Nucl Med. 1981;22:869-874.
29. Baldwin SA, Beal PR, Yao SY, et al. The equilibrative nucleoside transporter family, SLC29. Pflugers Arch. 2004;447:735-743.
30. Grierson JR, Shields AF, Zheng M, Kozawa SM, Courter JH. Radiosyntheses of labeled beta-pseudothymidine ([C-11]- and [H-3]methyl) and its biodistribution and metabolism in normal and tumored mice. Nucl Med Biol. 1995;22:671-678.
31. O'Sullivan F. Metabolic images from dynamic positron emission tomography studies. Stat Methods Med Res. 1994;3:87-101.
32. 14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem. 1977;28:897-916.
33. Spence AM, Muzi M, Graham MM, et al. Glucose metabolism in human malignant gliomas measured quantitatively with PET, 1-[C-11]glucose and FDG: analysis of the FDG lumped constant. J Nucl Med. 1998;39:440-448.
34. Muzi M, Freeman SD, Burrows RC, et al. Kinetic characterization of hexokinase isoenzymes from glioma cells: implications for FDG imaging of human brain tumors. Nucl Med Biol. 2001;28:107-116.
35. Bassingthwaighte JB, Chaloupka M. Sensitivity functions in the estimation of parameters of cellular exchange. Fed Proc. 1984;43:181-184.
36. Graham MM. Kinetic evaluation using sensitivity functions and correlation matrices [abstract]. J Nucl Med. 1995;36(suppl):268P.
37. 11C]thymidine PET imaging studies of malignant brain tumors: compartmental model investigation and mathematical analysis. Mol Imaging. 2002;1:151-159.
38. Alpert NM, Barker WC, Gelman A, et al. The precision of positron emission tomography: theory and measurement. J Cereb Blood Flow Metab. 1991;11: A26-A30.
39. 18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter. J Nucl Med. 2004;45:1653-1659.